ArticleClinical, cosmetic and investigational dermatology2026
Subtype-Specific Response to Fractional-Mode Q-Switched Ruby Laser in Melasma: A Prospective Single-Blind Clinical Study Using Clinical and Noninvasive Imaging Assessments.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Melasma is a chronic relapsing facial hyperpigmentation disorder with pigmentary and vascular heterogeneity. This study compared responses of pigmentary melasma (M), characterized predominantly by brown hyperpigmented macules or patches with non-dominant vascularity, and pigmentary-vascular melasma (M+V), characterized by pigmentation with persistent erythema or telangiectatic vascular features, to fractional-mode 694 nm Q-switched ruby laser. Methods: In this prospective, single-center, single-blind clinical study with assessor-blinded outcome evaluation, 100 women with facial melasma were classified at baseline as M (n = 50) or M+V (n = 50) by clinical examination and dermoscopy. All received three laser sessions at 4-week intervals. Outcomes included MASI, VISIA brown spots, ultraviolet spots, red areas, dermoscopic vascular scores, responder status, patient-reported improvement, satisfaction, and adverse events. Results: Ninety patients completed week 12 assessment (M, n = 42; M+V, n = 48). Week 12 MASI percentage reduction was 71.1% ± 13.5% in M versus 51.2% ± 12.3% in M+V ( Conclusion: Fractional-mode 694 nm Q-switched ruby laser improved both subtypes, but pigmentary melasma showed a more favorable response. Baseline clinicodermoscopic subtype classification and multimodal assessment may support individualized laser treatment and response evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.